Clinical Benefits as Endpoints in Advanced Non-Small Cell Lung Cancer Treated with Integrative Medicine.pdfVIP

下载本文档

12
0
约1.65万字
约 4页
2018-03-27 发布于湖北
举报
版权申诉

Clinical Benefits as Endpoints in Advanced Non-Small Cell Lung Cancer Treated with Integrative Medicine.pdf

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Clinical Benefits as Endpoints in Advanced Non-Small Cell Lung Cancer Treated with Integrative Medicine.pdf

· 228 · r：l7 31：2 ACADEMIC EXPLORATION ClinicalBenefitsasEndpointsinAdvancedNon--Small CellLungCancerTreatedwithIntegrativeMedicine XUEDong 薛冬 andLIPing-ping 李萍萍 ABSTRACT “Livingwithcancer“andsymptom controlarethefeaturesandadvantagesofintegrativemedicine Inadvancednon-smalIcellIungcancer NSCLC treatment．However，withthecurrentconceptofresponse evaluationcriteriabytheWHO andRECIST．itisdifficulttoexhibittheabovecharacteristics．Clinicalbenefit CB isdesignedasanendpointrecentlywidelyunderstoodandacceptedinoncologyclinicaltrials．W_lh thereview ofitsdefinitionanddevelopment．wesuggestCBtobeusedasanendpointinadvancedNSCLC treatmentwith integrativemedicine．CB shouldencompasstwoconnotations：one isimprovedqualityoflife andsymptomcontrolandtheotherisdiseasecontrolrate DCR ，includingcompleteresponse CR ，pa~ial response PR ，andstabledisease SD ．Weneedtodesignrandomizedcontrolledtrials RCT toinvestigate theinterrelationshipofCBrateandsurvivaltoprovidehigh-gradeevidenceprovingthatadvancedlungcancer patientscouldreallybenefitfr0m integrativemedicinetreatment。 KEYWORDS non-smalIcelllungcancer，Chinesemedicine，endpoints。clinicaIbenefit Luna cancer is one ofthe mostcommon performancestatusafterreceivingfirst．．1ineorsecond—- malignantdiseaseswithhighmorbidityandmortality linechemotherapy．CM isoneofthefollowingoptions rate．As estimated bY the U．S．Surve_lIance． inparallelwithpalliativecareorincluded inclinicaI EpidemiologyandEndResults SEER Program， trials。Thus．CM istheIaststraw forend．stageIung in2009．therewere219440 new casesoflungand cancerpatients．However．withourclinicaIexperience bronchuscancersand159390deathsareestimated andthehistoryofCM incancertreatment，werealized tooccurduetothisdisease1【J．1nChina．withreference thatCM shouIdbeimOIiedasearlyaspossible in totheChinesehealthannualbook．Iungcanceristhe cancertreatment，notiustattheendstage．One Ieadingcauseofcancerdeathsintheruralandurban systematicreview 。【carried outbySisisearched areasofChina J．OfaIlIungandbronchuscancers．